title: [A case report--Efficacy of combination therapy to unresectable advanced gall bladder carcinoma--palliative operation, hepatic arterial infusion therapy, and radiation therapy].
abstract: A patient of advanced gall bladder carcinoma with liver metastases and direct invasions to the duodenum and liver underwent a palliative operation, 3 hepatic arterial infusion (HAI) therapies, and radiation therapy at the obstructive common biliary duct. (Palliative operation was a partial resection of duodenum and transverse colon, HAI therapy with 5-FU (1 g/day) was given as a continuous infusion for 6 days, radiation therapy was given 2 Gy/day for 20 times) After the combination therapy, the main tumor of gall bladder and hepatic metastases were decreased and tumor markers were normalized. (CEA 15.1 ng/ml, CA19-9 93 U/ml to CEA 4.4 ng/ml, CA19-9 29 U/ml) Then, an expandable metallic stent (EMS) could be inserted to the stenotic common biliary duct after radiation therapy. Although para-aotic lymph nodes were existent, systemic chemotherapy (UFT 300 mg/day p.o., MMC 2 mg/week div) has been performed as an outpatient with a good quality of life.
authors.affiliation: Dept. of Surgery, Hyogo Prefectural Nishinomiya Hospital.
authors.forename: Itsurou
authors.initials: I
authors.lastname: Soma
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Hasuike
authors.forename: Nobuyasu
authors.initials: N
authors.lastname: Hayashi
authors.forename: Nariaki
authors.initials: N
authors.lastname: Fukuchi
authors.forename: Hikaru
authors.initials: H
authors.lastname: Izawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yoshida
authors.forename: Chikara
authors.initials: C
authors.lastname: Ebisui
authors.forename: Isao
authors.initials: I
authors.lastname: Sakita
authors.forename: Takayosi
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Koshino
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Izumiyama
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D004379:Duodenal Neoplasms / Q000473:pathology / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage*; D005706:Gallbladder Neoplasms / Q000628:therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use; D010166:Palliative Care; D015607:Stents; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D005472:Fluorouracil